The Galectin-1 level in serum as a novel marker for stress.
Galectin-1(Gal-1), a carbohydrate-binding protein with an affinity for beta-galactoside, is widely expressed in various normal and pathological tissues and it also plays an important role in regulating immune cell homeostasis and tumorigenesis. This study investigated the effects of restraint stress on serum Gal-1 by Western blot analyses and enzyme-linked immunosorbent assays. The Gal-1 levels of the restraint-stress group were significantly higher than those of the control group. However, this increase by stress was not obvious in adolescent rats. The pattern of these changes was similar to that of corticosterone. Furthermore, this Gal-1 increase in the serum was prevented by pre-treatment with a neurotoxin 6-hydroxydopamine (6-OHDA), which destroys the noradrenergic nerve terminals. However, a bilateral adrenalectomy (ADX) had no effect on the Gal-1 increase. These results suggest that Gal-1 is a candidate stress marker protein and that the stress-induced increase of Gal-1 in serum is regulated by the sympathetic nervous system under stress conditions.
Iwamoto
Mayuko
M
Department of Craniofacial Growth and Development Dentistry, Kanagawa Dental College, 82 Inaoka-Cho, Yokosuka, Kanagawa 238-8580, Japan.
Taguchi
Chiho
C
Sasaguri
Kenichi
K
Kubo
Kin-ya
KY
Horie
Hidenori
H
Yamamoto
Toshiharu
T
Onozuka
Minoru
M
Sato
Sadao
S
Kadoya
Toshihiko
T
D000315:Adrenalectomy; D000818:Animals; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D037483:Galectin 1 / Q000097:blood*; D008297:Male; D016627:Oxidopamine / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D013312:Stress, Physiological; D013563:Sympathectomy, Chemical
D037483:Galectin 1; D016627:Oxidopamine
Brain Res Dev Brain Res. 1996 Jul 20;94(2):144-51
8836572
Cancer. 1999 Dec 1;86(11):2353-63
10590378
Endocrinology. 2006 Apr;147(4):1664-74
16410296
J Immunol. 2008 Oct 1;181(7):4570-9
18802059
Eur J Immunol. 2000 May;30(5):1331-9
10820379
J Pharmacol Exp Ther. 1997 Mar;280(3):1296-303
9067316
Can J Physiol Pharmacol. 1971 Jan;49(1):36-44
5572416
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18472-7
19011096
J Neurosci. 2009 Feb 11;29(6):1826-33
19211889
Fed Proc. 1971 May-Jun;30(3):877-85
4324975
Exp Neurol. 2007 Oct;207(2):302-13
17706645
Glycoconj J. 2004;19(7-9):467-77
14758070
Ann N Y Acad Sci. 2002 Jun;966:20-7
12114255
Cytotechnology. 2008 Jun;57(2):181-5
19003164
Hepatology. 2000 Aug;32(2):268-77
10915733
Glycoconj J. 2004;19(7-9):575-81
14758082
J Dent Educ. 2003 Oct;67(10):1091-4
14587673
J Neurosci. 1999 Nov 15;19(22):9964-74
10559404
Glycobiology. 2006 Nov;16(11):137R-157R
16840800
J Pharmacol Exp Ther. 2003 Sep;306(3):1152-8
12829727
J Neurosci. 2004 Feb 25;24(8):1873-80
14985427
J Gastroenterol Hepatol. 2006 Jul;21(7):1099-102
16824059
J Pathol. 2004 Dec;204(5):511-8
15538736
Immunology. 1999 May;97(1):100-6
10447720
Physiol Behav. 1981 Oct;27(4):715-21
7198799
Psychoneuroendocrinology. 2001 Jul;26(5):443-59
11337130
Neuroscience. 1997 Jun;78(4):1059-68
9174074
Brain Res. 2007 Jun 25;1155:108-15
17511973
Braz J Med Biol Res. 1999 May;32(5):557-67
10412567
Oral Oncol. 2008 Jan;44(1):86-93
17350328